25 April 2023: Ionis Pharmaceuticals, Inc today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval…
Category: Amyotrophic Lateral Sclerosis (ALS)
Study finds Pison AI technology can detect neurological disorder in ALS patients
Lewis Katz School of Medicine at Temple University research shows Pison’s Neural Biosensor can potentially enable remote monitoring, early detection and intervention for neurological diseases Pison have announced the results of recent clinical trial conducted by researchers at the Lewis Katz School of Medicine at Temple University’s MDA/ALS Center of Hope, in the US. The trials concluded…
Pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for pridopidine for the treatment of ALS. Prilenia recently received a positive opinion from the Committee of Orphan Medicinal Products (COMP) in…
